Taken all the results together, it is inferred that ZNF300 may act as a potential therapeutic target in MDS and AML against disease progression, and using ZNF300-based targeted therapy could improve the clinical outcome for MDS and AML patients. Here, ZNF300 is linked to acute myeloid leukemia.